OBJECTIVES: Etravirine has high affinity for plasma drug-binding proteins, such as albumin and α1-acid glycoprotein, which limits the amount of unbound etravirine available to enter the CNS. The objective of this study was to compare total and unbound etravirine concentrations in CSF with plasma concentrations and the in vitro median inhibitory concentration (IC50) for wild-type HIV (0.9 ng/mL). METHODS: Total and bound etravirine concentrations were measured in 17 CSF and plasma pairs by isotope-dilution liquid chromatography tandem mass spectroscopy, radioligand displacement and ultracentrifugation. Unbound etravirine concentrations were calculated from the bound fraction. The dynamic range of the assay was 7.8-2000 (plasma) and 0.78-200 (CSF) ng/mL. RESULTS: Subjects were mostly middle-aged (median 43 years) white (78%) men (89%). All CSF etravirine concentrations were above the limit of quantification. Total and unbound median etravirine concentrations in CSF were 9.5 (IQR 6.4, 26.4) and 0.13 (IQR 0.08, 0.27) ng/mL, respectively. Etravirine was 96% (IQR 94.5, 97.2) protein bound in plasma and 98.4% (IQR 97.8, 98.8) in CSF. Total etravirine in CSF was 4.3% (IQR 3, 5.9) of total and 101% (IQR 76, 160) of unbound etravirine in plasma. There were no significant correlations between unbound etravirine concentrations and concentrations of albumin in plasma or CSF. Unbound etravirine concentrations in CSF did not reach the wild-type IC50 in any of the specimens. CONCLUSIONS: Unbound etravirine may not achieve optimal concentrations to inhibit HIV replication in the CNS.
OBJECTIVES:Etravirine has high affinity for plasma drug-binding proteins, such as albumin and α1-acid glycoprotein, which limits the amount of unbound etravirine available to enter the CNS. The objective of this study was to compare total and unbound etravirine concentrations in CSF with plasma concentrations and the in vitro median inhibitory concentration (IC50) for wild-type HIV (0.9 ng/mL). METHODS: Total and bound etravirine concentrations were measured in 17 CSF and plasma pairs by isotope-dilution liquid chromatography tandem mass spectroscopy, radioligand displacement and ultracentrifugation. Unbound etravirine concentrations were calculated from the bound fraction. The dynamic range of the assay was 7.8-2000 (plasma) and 0.78-200 (CSF) ng/mL. RESULTS: Subjects were mostly middle-aged (median 43 years) white (78%) men (89%). All CSFetravirine concentrations were above the limit of quantification. Total and unbound median etravirine concentrations in CSF were 9.5 (IQR 6.4, 26.4) and 0.13 (IQR 0.08, 0.27) ng/mL, respectively. Etravirine was 96% (IQR 94.5, 97.2) protein bound in plasma and 98.4% (IQR 97.8, 98.8) in CSF. Total etravirine in CSF was 4.3% (IQR 3, 5.9) of total and 101% (IQR 76, 160) of unbound etravirine in plasma. There were no significant correlations between unbound etravirine concentrations and concentrations of albumin in plasma or CSF. Unbound etravirine concentrations in CSF did not reach the wild-type IC50 in any of the specimens. CONCLUSIONS: Unbound etravirine may not achieve optimal concentrations to inhibit HIV replication in the CNS.
Authors: Christine Katlama; Bonaventura Clotet; Anthony Mills; Benoit Trottier; Jean-Michel Molina; Beatriz Grinsztejn; William Towner; Richard Haubrich; Steven Nijs; Johan Vingerhoets; Brian Woodfall; James Witek Journal: Antivir Ther Date: 2010
Authors: David Croteau; Steven S Rossi; Brookie M Best; Edmund Capparelli; Ronald J Ellis; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Igor Grant; Scott Letendre Journal: J Antimicrob Chemother Date: 2012-11-09 Impact factor: 5.790
Authors: K T Tashima; A M Caliendo; M Ahmad; J M Gormley; W D Fiske; J M Brennan; T P Flanigan Journal: J Infect Dis Date: 1999-09 Impact factor: 5.226
Authors: D W Haas; J Stone; L A Clough; B Johnson; P Spearman; V L Harris; J Nicotera; R H Johnson; S Raffanti; L Zhong; P Bergqwist; S Chamberlin; V Hoagland; W D Ju Journal: Clin Pharmacol Ther Date: 2000-10 Impact factor: 6.875
Authors: Koen Andries; Hilde Azijn; Theo Thielemans; Donald Ludovici; Michael Kukla; Jan Heeres; Paul Janssen; Bart De Corte; Johan Vingerhoets; Rudi Pauwels; Marie-Pierre de Béthune Journal: Antimicrob Agents Chemother Date: 2004-12 Impact factor: 5.191
Authors: F T Aweeka; A Stek; B M Best; C Hu; D Holland; A Hermes; S K Burchett; J Read; M Mirochnick; E V Capparelli Journal: HIV Med Date: 2009-12-03 Impact factor: 3.180
Authors: R Ter Heine; H Rosing; E C M van Gorp; J W Mulder; J H Beijnen; A D R Huitema Journal: J Pharm Biomed Anal Date: 2008-11-05 Impact factor: 3.935
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Marta Boffito; David J Back; Terrence F Blaschke; Malcolm Rowland; Richard J Bertz; John G Gerber; Veronica Miller Journal: AIDS Res Hum Retroviruses Date: 2003-09 Impact factor: 2.205
Authors: Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart Journal: Clin Pharmacokinet Date: 2016-03 Impact factor: 6.447
Authors: Nicholas Pagano; Peter Teriete; Margrith E Mattmann; Li Yang; Beth A Snyder; Zhaohui Cai; Marintha L Heil; Nicholas D P Cosford Journal: Bioorg Med Chem Date: 2017-04-08 Impact factor: 3.641
Authors: Nithya Srinivas; Elias P Rosen; William M Gilliland; Martina Kovarova; Leila Remling-Mulder; Gabriela De La Cruz; Nicole White; Lourdes Adamson; Amanda P Schauer; Craig Sykes; Paul Luciw; J Victor Garcia; Ramesh Akkina; Angela D M Kashuba Journal: Xenobiotica Date: 2018-12-17 Impact factor: 1.908
Authors: Eugene L Asahchop; Oussama Meziane; Manmeet K Mamik; Wing F Chan; William G Branton; Lothar Resch; M John Gill; Elie Haddad; Jean V Guimond; Mark A Wainberg; Glen B Baker; Eric A Cohen; Christopher Power Journal: Retrovirology Date: 2017-10-16 Impact factor: 4.602